IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.

Front Immunol · 2018 · PMC6143659 · PMID 30258440

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In conclusion, a substantial and statistically highly significant reduction of C5a receptors was observed in NSTEMI patients treated with tocilizumab, and as for C5aR1, the downregulation correlated with attenuated TnT release.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.